For example, although MGMT methylation status was not prospectively assayed in the pivotal EORTC/NCIC trial of adjuvant TMZ in adults with glioblastoma, patients with tumors exhibiting unmethylated MGMT promoter regions derived less benefit [24, 25]. The gene discussed is MGMT; the disease is glioblastoma.